| Literature DB >> 24008661 |
J P Väyrynen1, A Tuomisto, K Klintrup, J Mäkelä, T J Karttunen, M J Mäkinen.
Abstract
BACKGROUND: Higher-grade inflammatory infiltrate is a promising marker for better prognosis in colorectal cancer (CRC). However, the knowledge on the interrelationships between different inflammatory cells and classifications is fragmentary.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24008661 PMCID: PMC3790164 DOI: 10.1038/bjc.2013.508
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Patient characteristics
| Age, mean (s.d.) | 67.7 (11.2) |
| Male | 58 (49.6%) |
| Female | 59 (50.4%) |
| Yes | 0 (0%) |
| No | 117 (100%) |
| Proximal colon | 49 (41.9%) |
| Distal colon | 28 (23.9%) |
| Rectum | 40 (34.2%) |
| G1 (well) | 16 (13.8%) |
| G2 (moderately) | 86 (74.1%) |
| G3 (poorly) | 14 (12.1%) |
| Stage I | 19 (16.5%) |
| Stage II | 46 (40%) |
| Stage III | 32 (27.8%) |
| Stage IV | 18 (15.7%) |
| MMR proficient | 105 (90.5%) |
| MMR deficient | 11 (9.5%) |
Abbreviations: MMR=mismatch repair; RT/CRT=radiotherapy or chemoradiotherapy; TNM=tumour, node, metastasis; WHO=World Health Organization.
Figure 1Representative images of immunohistochemical determination of eight inflammatory cell types in colorectal cancer: CD3 for T cells, CD8 for cytotoxic T cells, FoxP3 for regulatory T cells, CD68 for monocyte–macrophage lineage cells, CD83 for mature dendritic cells, CD1a for immature dendritic cells, mast cell tryptase for mast cells, and neutrophil elastase for neutrophilic granulocytes.
Interrelationships between different inflammatory cell types in colorectal cancer
| CD3i | 0.162 | 0.175 | 0.054 | 0.113 | 0.057 | ||||||||||||
| CD3s | | 0.012 | 0.142 | −0.063 | 0.053 | 0.113 | 0.015 | ||||||||||
| CD3e | | | 0.020 | 0.051 | 0.038 | 0.052 | 0.174 | 0.067 | |||||||||
| CD8i | | | | 0.097 | 0.147 | 0.014 | 0.086 | ||||||||||
| CD8s | | | | | 0.173 | 0.104 | 0.146 | 0.070 | 0.043 | 0.145 | −0.003 | ||||||
| CD8e | | | | | | −0.024 | −0.009 | 0.062 | −0.066 | 0.043 | |||||||
| FoxP3i | | | | | | | 0.117 | 0.044 | 0.090 | ||||||||
| FoxP3s | | | | | | | | 0.061 | 0.179 | ||||||||
| CD68i | | | | | | | | | 0.146 | 0.060 | 0.175 | ||||||
| CD68s | | | | | | | | | | 0.080 | 0.132 | 0.037 | |||||
| CD83i | | | | | | | | | | | 0.114 | ||||||
| CD83s | | | | | | | | | | | | 0.045 | −0.083 | ||||
| CD1a_i | | | | | | | | | | | | | 0.138 | ||||
| CD1a_s | | | | | | | | | | | | | | 0.169 | 0.080 | ||
| Mast_i | | | | | | | | | | | | | | | 0.019 | −0.037 | |
| Mast_s | | | | | | | | | | | | | | | | −0.018 | 0.157 |
| Neut_i |
Abbreviations: e= intraepithelial; i=invasive front (peritumoural); Mast=mast cell tryptase; Neut=neutrophil elastase; s=stromal (intratumoural).
Numbers indicate Pearson's correlation coefficients for logarithmically transformed variables. Statistically significant coefficients are in bold.
Figure 2Dendrogram for hierarchical clustering of eight inflammatory cells in CRC. Nearest neighbour method with standardised squared Euclidean distance was used. Mast cells and CD1a+ immature DCs clustered furthest from other cell types (at the bottom). These cell types also had the weakest associations with stage (Table 4). Instead, T cells, forming a cluster at the top along with CD83+ mature DCs, had the highest associations with stage (Table 4), recurrences (Table 5), and MMR deficiency (Supplementary Table 4), supporting their importance in CRC defence.
Relationship between individual inflammatory cell types and Klintrup–Mäkinen classification of peritumoural inflammation
| | | ||
|---|---|---|---|
| CD3, invasive front | 401.0 (193.3–568.4) | 1095.6 (640.6–1344.4) | 1.9E−13 |
| CD3, stroma | 297.8 (133.9–509.5) | 697.0 (454.9–1037.5) | 4.5E−7 |
| CD3, intraepithelial | 16.9 (5.3–33.1) | 85.0 (22.9–128.9) | 9.6E−9 |
| CD8, invasive front | 110.8 (56.3–240.6) | 299.0 (155.9–574.5) | 5.9E−7 |
| CD8, stroma | 65.7 (22.0–145.6) | 163.5 (60.1–311.3) | 1.8E−4 |
| CD8, intraepithelial | 8.4 (2.6–23.4) | 48.9 (13.2–92.9) | 1.1E−7 |
| FoxP3, invasive front | 105.5 (51.4–188.9) | 227.0 (139.1–395.6) | 1.3E−7 |
| FoxP3, stroma | 107.9 (51.2–181.3) | 253.9 (108.6–396.3) | 6.9E−4 |
| CD68, invasive front | 389.2 (245.0–614.1) | 755.0 (538.4–1132.9) | 6.8E−9 |
| CD68, stroma | 240.9 (167.7–462.5) | 504.7 (297.2–731.3) | 8.5E−6 |
| CD1a, invasive front | 7.7 (2.3–22.1) | 11.9 (5.7–18.2) | 0.331 |
| CD1a, stroma | 6.6 (2.4–13.2) | 10.6 (3.1–15.8) | 0.145 |
| CD83, invasive front | 3.5 (1.4–7.0) | 10.8 (7.1–19.3) | 9.9E−10 |
| CD83, stroma | 3.2 (1.3–6.5) | 5.8 (2.2–12.0) | 2.7E−3 |
| Mast cell tryptase, invasive front | 37.5 (24.0–64.8) | 45.5 (27.3–82.1) | 0.199 |
| Mast cell tryptase, stroma | 34.0 (20.4–58.0) | 45.7 (25.4–73.3) | 0.065 |
| Neutrophil elastase, invasive front | 18.8 (7.0–105.8) | 111.8 (18.0–386.4) | 1.1E−3 |
| Neutrophil elastase, stroma | 22.5 (8.8–80.9) | 56.3 (17.9–141.9) | 0.016 |
The P-values are for Mann–Whitney U-test.
Local inflammatory cell infiltration in different TNM (tumour, node, metastasis) stages
| | | ||||
|---|---|---|---|---|---|
| CD3, invasive front | 1120.2 (668.3–1253.3) | 566.9 (397.1–867.7) | 573.5 (307.9–927.8) | 205.2 (146.1–434.4) | 1.5E−5 |
| CD3, stroma | 735.1 (412.7–1187.4) | 517.7 (223.9–858.6) | 379.6 (225.1–651.5) | 223.6 (110.8–510.3) | 6.6E−3 |
| CD3, intraepithelial | 72.1 (23.9–159.4) | 26.1 (10.2–97.8) | 22.7 (14.1–78.7) | 10.6 (4.8–35.6) | 2.8E−3 |
| CD8, invasive front | 265.5 (159.4–495.9) | 184.1 (100.2–381.1) | 149.5 (74.1–436.1) | 95.0 (25.0–176.3) | 4.7E−3 |
| CD8, stroma | 175.9 (42.2–260.3) | 98.8 (55.1–210.4) | 91.7 (26.8–237.8) | 25.6 (13.5–84.7) | 8.5E−3 |
| CD8, intraepithelial | 23.9 (10.6–112.6) | 22.0 (6.6–63.3) | 27.3 (4.2–59.5) | 6.2 (1.7–19.0) | 0.012 |
| FoxP3, invasive front | 276.7 (222.8–416.2) | 158.8 (85.3–312.7) | 147.7 (74.8–280.2) | 54.2 (27.0–106.6) | 1.6E−7 |
| FoxP3, stroma | 250.9 (156.5–389.2) | 142.8 (91.0–381.9) | 121.7 (63.7–284.3) | 42.5 (20.2–73.6) | 9.7E−6 |
| CD68, invasive front | 619.0 (269.9–975.4) | 647.1 (390.1–899.9) | 495.9 (292.8–778.0) | 361.1 (246.8–544.5) | 0.055 |
| CD68, stroma | 277.9 (186.4–607.2) | 410.3 (224.2–597.0) | 393.7 (187.6–637.5) | 311.3 (189.3–476.3) | 0.629 |
| CD1a, invasive front | 16.2 (11.14–25.32) | 10.4 (1.8–21.0) | 10.6 (5.6–21.8) | 4.0 (2.0–11.9) | 0.012 |
| CD1a, stroma | 10.6 (7.6–22.9) | 10.1 (2.7–15.3) | 7.3 (3.5–12.9) | 5.8 (1.0–15.3) | 0.208 |
| CD83, invasive front | 14.1 (7.0–21.7) | 6.3 (3.24–11.5) | 8.57 (2.26–12.7) | 2.3 (0.88–6.51) | 3.2E−4 |
| CD83, stroma | 7.0 (2.6–16.3) | 4.1 (1.7–7.7) | 5.4 (2.7–8.7) | 1.9 (0.55–4.9) | 8.6E−3 |
| Mast cell tryptase, invasive front | 65.7 (29.9–105.5) | 38. (24.4–82.1) | 39.9 (24.0–69.8) | 39.0 (24.2–50.1) | 0.299 |
| Mast cell tryptase, stroma | 56.3 (35.2–91.4) | 36.1 (17.4–72.7) | 37.2 (25.4–60.5) | 39.3 (20.5–46.6) | 0.163 |
| Neutrophil elastase, invasive front | 98.5 (11.7-397.9) | 60.7 (14.1–273.5) | 52.1 (10.8–291.5) | 9.1 (4.8–40.8) | 0.079 |
| Neutrophil elastase, stroma | 56.3 (9.4–123.1) | 39.9 (10.6–166.3) | 32.5 (7.6–100.8) | 25.3 (8.79–128.6) | 0.545 |
Numbers indicate cells mm−2. The P-values are for Kruskal–Wallis test.
The 24-month recurrence analysis
| CD3, invasive front | 0.655 | 0.502–0.808 | 600 | |
| CD3, stroma | 0.659 | 0.526–0.793 | 580 | 0.095 |
| CD3, intraepithelial | 0.612 | 0.480–0.744 | 24 | 0.181 |
| CD8, invasive front | 0.522 | 0.346–0.698 | 110 | 0.220 |
| CD8, stroma | 0.624 | 0.464–0.784 | 80 | 0.150 |
| CD8, intraepithelial | 0.553 | 0.399–0.708 | 15 | 0.373 |
| FoxP3, invasive front | 0.699 | 0.551–0.847 | 150 | |
| FoxP3, stroma | 0.691 | 0.543–0.839 | 125 | |
| CD68, invasive front | 0.637 | 0.487–0.788 | 480 | 0.080 |
| CD68, stroma | 0.499 | 0.340–0.659 | 380 | 0.619 |
| CD1a, invasive front | 0.469 | 0.332–0.606 | 16 | 0.963 |
| CD1a, stroma | 0.475 | 0.313–0.636 | 10 | 0.472 |
| CD83, invasive front | 0.525 | 0.360–0.690 | 13 | 0.514 |
| CD83, stroma | 0.525 | 0.374–0.677 | 7 | 0.351 |
| Mast cell tryptase, invasive front | 0.498 | 0.328–0.668 | 40 | 0.525 |
| Mast cell tryptase, stroma | 0.490 | 0.346–0.633 | 40 | 0.837 |
| Neutrophil elastase, invasive front | 0.527 | 0.375–0.679 | 150 | 0.413 |
| Neutrophil elastase, stroma | 0.564 | 0.405–0.722 | 110 | 0.150 |
| Klintrup–Mäkinen score (4-tiered) | 0.681 | 0.548–0.840 | — | |
| Klintrup–Mäkinen score (2-tiered) | 0.626 | 0.470–0.781 | — | 0.093 |
Abbreviations: AUC=area under the curve; CI=confidence interval.
The table presents receiver operating characteristics (ROC) analysis, AUCs, and log-rank P-values for different inflammatory variables in detecting recurrences. Statistically significant P-values are in bold.